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EDITORIAL 
 
Clinical Practice Guidelines play an important role in the management of inherited metabolic 
diseases. Effective diagnosis and treatment is a particular challenge for rare diseases 
requiring specialist knowledge. The increasing availability of highly specific – and highly 
expensive – treatments for a rapidly growing number of rare conditions adds another 
dimension to the need for reliable guidelines. In order to justify the high costs of novel 
treatments it is essential that treatment is evidence-based and provided only to patients 
who will have a clear benefit. One of the main aims of the JIMD is to support the collation 
and publication of studies that provide a comprehensive, representative analysis of the 
clinical features, treatment and outcome of an inborn error of metabolism. The SSIEM’s 
annual Archibald Garrod Award is given to the lead author of any such publication published 
in the preceding year in the JIMD. A major benefit of these studies is to provide an evidence 
base for the formulation of clinical practice guidelines, and the JIMD is very happy to 
consider such guidelines for publication.  
 
Unfortunately limited resources are available to support the tedious and often undervalued 
effort needed to write reliable clinical practice guidelines. Frequently, only the 
pharmaceutical industry is willing to fund this work, sometimes because there is a strong 
interest in identifying additional patients who qualify for treatment and will generate 
revenue for industry. This creates immediate conflicts of interest that may be difficult to 
address (even if they are fully stated) in publications reporting clinical practice guidelines. On 
the other hand, close collaboration between clinicians and industry is often an important 
factor in optimizing care for patients with rare diseases including many inherited metabolic 
diseases. Furthermore, for some conditions it is difficult to find experienced clinicians who 
have no connections to industry. This also poses a particular challenge for the Editors and 
Reviewers of the JIMD when they assess a manuscript reporting clinical practice guidelines. 
Herewith we wish to state general principles for such manuscripts submitted to the JIMD. 
These principles address two aspects: (a) the consultation and review process leading to the 
formulation of clinical practice guidelines, and (b) independence from industry of the 
authors. 
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Rules for guideline development processes 
Published clinical practice guidelines are of very variable quality and it has been long 
recognized that they may be influenced by industry funding (Choudhry et al. 2002). Many 
“guidelines” are in fact “expert consensus reports” based on expert opinion without 
systematic literature analysis and thus represent the lowest level of evidence (Shaneyfelt 
and Centor 2009; Shaneyfelt et al. 1999). In order to provide guidance for guideline 
development, an international collaboration denoted AGREE (Appraisal of Guidelines, 
Research and Evaluation) was established and a 23-item tool comprising six quality-related 
domains was released in 2003 and revised in 2010 (Brouwers et al. 2010). Details of this 
instrument including a user’s guide are available at the collaboration website 
www.agreetrust.org (accessed 28.02.2016). Extensive information on the GRADE (Grading of 
Recommendations Assessment, Development, and Evaluation) system of rating quality of 
evidence and grading strength of recommendations was published in a series of 15 articles in 
2011 (Guyatt et al. 2011). National organisations such as the German Association of 
Scientific Medical Societies (AWMF; see http://www.awmf.org/leitlinien/awmf-
regelwerk.html, accessed 28.02.2016) and the British Inherited Metabolic Diseases Group 
(BIMDG: see http://www.bimdg.org.uk/site/guidelines.asp, accessed 26.01.2016) have 
created framework structures for the publication of clinical practice guidelines on a wide 
range of topics (Muche-Borowski et al. 2012).   
 
While a formalized review of the published medical evidence is clearly the preferred method 
for guideline development, this is not always feasible given the available resources. The 
Delphi method (Dalkey 1996) has been used to generate useful suggestions for the 
management of specific rare inherited metabolic diseases in a systematic fashion, based on 
the opinions of a large number of experts. This approach involves circulation of 
questionnaires to a large number of individuals across diverse locations, and repeated 
rounds of discussion, until consensus is reached. A review of the application of the Delphi 
method in medicine highlighted the need for adequate selection of panel members based on 
their knowledge and willingness to participate, and careful definition of study objectives and 
design of the questionnaire (Boulkedid et al. 2011). 
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The statistical evidence used to guide therapeutic choices in common disorders is not 
available for most rare diseases including inborn metabolic diseases. In many instances 
therapeutic choices are based on physicians’ personal experiences, and “compassionate use” 
of drugs may be based on single case reports. In other cases the literature is not in 
agreement, or there is no reported evidence, just a known disease mechanism which is used 
to create a unique individualized treatment plan. This should be taken into account during 
prognostication and therapeutic counselling. It is hoped that establishment of networks of 
experts caring for larger numbers of “orphan” patients, together with good prospective data 
registration during observational or therapeutic trials, will overcome these problems in the 
future. 
 
The JIMD considers it mandatory that the evidence underpinning recommendations or 
guidelines has been collated in a systematic and objective fashion. Patients entered into 
disease-specific registries must have an enzymatic and/or molecular confirmation of their 
disease, except in instances where a specific diagnosis can be reliably based on clinical 
and/or biochemical findings. Systematic review of the available medical literature should be 
performed using an established methodology. Alternatively, if the aim of the publication is 
an expert consensus report, the Editors of the JIMD require a (modified) Delphi method to 
be used. Authors are requested to describe the reason for selection of the panel experts and 
provide the questionnaires used, for publication as supplementary material. Authors should 
state in the title of their paper whether it constitutes "guidelines" or "consensus of expert 
opinion". Recommendations or guidelines arising from informal symposia and other 
meetings do not fulfil these criteria and therefore will not be accepted for publication in the 
JIMD. 
 
Conflicts of interest 
The need to consider possible conflicts of interest in the development of guidelines for 
diagnosis and treatment for rare diseases, and more generally in maintaining the scientific 
integrity and independence of future “European Reference Networks” (ERNs), has been 
highlighted in a recently published position statement (Hollak et al. 2016). It is the JIMD 
Editors’ opinion that the general rules outlined in that manuscript also apply to 
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recommendations and guidelines published in the JIMD, as follows. 
 
Groups that develop clinical practice guidelines should generally exclude as panel members 
individuals with conflicts of interest and should not accept direct funding for clinical practice 
guideline development from medical product companies or company foundations. Groups 
should publicly disclose with each guideline their conflict of interest policies and procedures 
and the sources and amounts of indirect or direct funding received for development of the 
guideline. In the situation in which avoidance of panel members with conflicts of interest is 
impossible because of the critical need for their expertise, then groups should: 
• publicly document that they made a good-faith effort to find experts without 
conflicts of interest by issuing a public call for members and other recruitment 
measures; 
• appoint a coordinator (chair) without a conflict of interest; 
• limit members with conflicting interests to an agreed part of the panel; 
• exclude individuals with serious conflicts of interest; 
• publicly disclose the relevant conflicts of interest of panel members. 
 
Healthcare professionals and patient representatives cannot take part in the publication of 
care pathways, treatment guidelines and diagnostic strategies if they have the following 
serious conflicts of interest relevant to the topic of the publication (at present, in the past 
three years, or in the foreseeable future): 
• are employed by a company with commercial interest; 
• have equity or other ownership interests in a company with commercial interest; 
• receive fees for work related activities into a personal bank account; 
• receive fees (paid to their institution, not for personal use) that are disproportionate 
to the work done (i.e., maximum fee more than locally agreed standards per hour). 
 
A participant in the development of care pathways, treatment guidelines and diagnostic 
strategies can have the following conflicts of interest relevant to the topic of the publication, 
provided that these relationships are fully disclosed and compensation (not for personal use) 
is reasonable and in line with local standards: 
• performing activities in the context of clinical trials;  
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• performing consultancies for a pharmaceutical company; 
• giving presentations during meetings organized by a pharmaceutical company;  
• receiving reasonable reimbursement of travel and hotel costs as part of meetings 
organized by a pharmaceutical company. 
 
For background discussion of these rules see the full published position statement (Hollak et 
al. 2016). These rules should not be seen as discouraging fruitful interactions between 
industry, healthcare professionals, and patient representatives. Rather, safeguarding 
independence of diagnostic and treatment guidelines from commercial interests will give 
these guidelines more weight and will protect all parties involved from claims that the 
published statements do not represent current standards of care. 
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